Roche's Lunsumio and Columvi are the first bispecific antibodies for lymphoma treatment, showing effectiveness as a third-line treatment for patients with lymphoma. These two drugs are highly regarded for their clinical advantages, as they have additional specific antigen-binding sites compared to monoclonal antibodies.

Roche Korea held a media session on the 3rd, celebrating the Korean approval of CD20/CD3 bispecific antibodies Lunsumio (mosunetuzumab-axgb) and Columvi (glofitamab).

Lunsumio is a CD20/CD3 T-cell engaging bispecific antibody that was initially indicated to treat relapsed or refractory diffuse large B cell lymphoma (DLBCL).

Lunsumio received appro